Benzinga

A veteran trader has made a bullish forecast that Bitcoin could reach as much as $600,000 in a best-case scenario. The claim, reported by Benzinga, is circulating among crypto commentators, with readers debating whether such a price target is realistic given Bitcoin's history of extreme volatility and past cycles of dramatic highs and deep corrections.

Kodiak Sciences announced that its experimental eye drug performs on par with Regeneron's established treatment, according to a Benzinga report. The claim, if supported by trial data, would position the biotech as a credible challenger in the competitive market for retinal disease therapies, where Regeneron's medicine has long been a dominant option.

AMC Entertainment shares are drawing attention as investors ask what is driving the movie theater chain's stock movement on Monday. Benzinga highlights the question, reflecting renewed interest in the company among retail traders who have long tracked its volatile price swings. No specific cause for Monday's move has been confirmed.